tera.ai

Knowledge Graph

Graph explorer

Search resolved entities, walk their edges, and read the sentence behind every one.

Entities25 of 207,987

All entities

Entity

REZILIENT3 Phase 3 trial

publication2 mentionslast seen Oct 2, 2026

A multicenter, randomized, controlled, open-label global trial evaluating zipalertinib plus chemotherapy versus chemotherapy alone in first-line treatment of patients with EGFR exon 20 insertion mutation NSCLC.

Relationships 1

REZILIENT3 Phase 3 trial

Relationship

REZILIENT3 Phase 3 trialciteszipalertinib

80% confidence1 supporting mentions

Either name opens that entity’s relationships.

Sources 1